LEADER 01682oam  2200457   450 
001 9910713434003321
005 20200430092947.0
035   $a(CKB)5470000002501315
035   $a(OCoLC)640889568
035   $a(EXLCZ)995470000002501315
100   $a20100613d1999      ua             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aPrescription drug benefits: impact of Medicare HMO's use of formularies on beneficiaries $etestimony before the Special Committee on Aging, U.S. Senate /$fstatement of William J. Scanlon
210  1$aWashington, D.C. :$cUnited States General Accounting Office,$d1999.
215   $a1 online resource (7 pages)
225 1 $aTestimony ;$vGAO/T-HEHS-99-171
300   $a"For release on delivery expected at 2:30 p.m. Tuesday, July 20, 1999."
320   $aIncludes bibliographical references.
517   $aPrescription drug benefits
606   $aDrugs$zUnited States$xCost control
606   $aHealth maintenance organizations$zUnited States
606   $aMedicare
606   $aPrescription pricing$zUnited States
615  0$aDrugs$xCost control.
615  0$aHealth maintenance organizations
615  0$aMedicare.
615  0$aPrescription pricing
702   $aScanlon$b William J.
712 02$aUnited States.$bCongress.$bSenate.$bSpecial Committee on Aging,
801  0$bAD#
801  1$bAD#
801  2$bOCLCQ
801  2$bGPO
906   $aBOOK
912   $a9910713434003321
996   $aPrescription drug benefits: impact of Medicare HMO's use of formularies on beneficiaries$93450772
997   $aUNINA